Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 29;15(13):3402.
doi: 10.3390/cancers15133402.

The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making-The Urological Perspective

Azik Hoffman  1 , Gilad E Amiel  1
Affiliations
Review

The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making-The Urological Perspective

Azik Hoffman et al. Cancers (Basel). .

Abstract

Prostate-specific membrane antigen (PSMA) PET use in prostate cancer treatment has recently become a routinely used imaging modality by urologists. New, established data regarding its performance in different stages of prostate cancer, as well as gaining clinical knowledge with new tracers, drives the need for urologists and other clinicians to improve the utilization of this tool. While the use of PSMA PET/CT is more common in metastatic disease, in which it outperforms classical imaging modalities and drives treatment decisions and adjustments, recently, it gained ground in localized prostate cancer as well, especially in high-risk disease. Still, PSMA PET/CT might reveal lesions within the prostate or possibly locoregional or metastatic disease, not always representing true cancer when utilized in earlier stages of the disease, potentially adding diagnostic burden and changing treatment decisions. As urological treatment options advance toward focal treatments in localized organ-confined prostate cancer, recent reports suggest the utilization of PSMA PET/CT in treatment planning and follow-up and even when choosing active surveillance. This review aims to reveal the current perspective of urologists regarding its daily use.

Keywords: PET CT; PSMA; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Real-life added value of PSMA PET/CT in prostate cancer treatment.
Figure 2
Figure 2
68Ga-PSMA Utilization in Real-Life Prostate Cancer Management: (A) 61 yo patient, PSA-6.1mg/ml. PIRAD 3 lesion detected in MRI. 68Ga-PSMA PET CT revealed SUVmax 10.6 uptake on the Rt side. Targeted biopsy detected ISUP3 PCa. (B) 67 yo patient, was referred for surgery due to high volume ISUP2 PCa on prostate biopsy. 68Ga-PSMA PET CT uptake in the Lt rib without an apparent lesion on CT, concluded as equivocal when revised. PSA remained undetectable for 1 year following surgery. (C) 72 yo patient, PSA 1.05 mg/ml 4.5 years following external beam radiation therapy. 68Ga-PSMA PET/CT imaging revealed Lt side local recurrence. Targeted biopsy detected ISUP3 PCa.
See this image and copyright information in PMC

References

    1. Awenat S., Piccardo A., Carvoeiras P., Signore G., Giovanella L., Prior J.O., Treglia G. Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review. Diagnostics. 2021;11:552. doi: 10.3390/diagnostics11030552. - DOI - PMC - PubMed
    1. Fanti S., Goffin K., Hadaschik B.A., Herrmann K., Maurer T., MacLennan S., Oprea-Lager D.E., Oyen W.J., Rouvière O., Mottet N., et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:469–476. doi: 10.1007/s00259-020-04934-4. - DOI - PMC - PubMed
    1. Mottet N., van den Bergh R.C.N., Briers E., van den Broeck T., Cumberbatch M.G., De Santis M., Fanti S., Fossati N., Gandaglia G., Gillessen S., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2021;79:243–262. doi: 10.1016/j.eururo.2020.09.042. - DOI - PubMed
    1. Cornford P., van den Bergh R.C.N., Briers E., van den Broeck T., Cumberbatch M.G., De Santis M., Fanti S., Fossati N., Gandaglia G., Gillessen S., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur. Urol. 2021;79:263–282. doi: 10.1016/j.eururo.2020.09.046. - DOI - PubMed
    1. Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Mason M., Matveev V., Wiegel T., Zattoni F., et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur. Urol. 2014;65:467–479. doi: 10.1016/j.eururo.2013.11.002. - DOI - PubMed